董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jean Pierre Bizzari | 男 | Independent Director | 70 | 25.63万美元 | 未持股 | 2025-12-04 |
| Bernadette Connaughton | 女 | Independent Director | 66 | 27.13万美元 | 未持股 | 2025-12-04 |
| Moni Miyashita | 女 | Independent Director | 69 | 未披露 | 未持股 | 2025-12-04 |
| Mahesh Krishnan | 男 | Independent Director | 54 | 未披露 | 未持股 | 2025-12-04 |
| James Lang | -- | Director | -- | 未披露 | 未持股 | 2025-12-04 |
| Connie L. Matsui | 女 | Chair of the Board and Independent Director | 71 | 29.00万美元 | 未持股 | 2025-12-04 |
| Jeffrey W. Henderson | 男 | Independent Director | 60 | 29.00万美元 | 未持股 | 2025-12-04 |
| Barbara Duncan | 女 | Independent Director | 60 | 未披露 | 未持股 | 2025-12-04 |
| Matthew L. Posard | 男 | Independent Director | 58 | 27.38万美元 | 未持股 | 2025-12-04 |
| Helen I. Torley | 女 | Chief Executive Officer, Independent Director and President | 62 | 651.89万美元 | 未持股 | 2025-12-04 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Nicole LaBrosse | 女 | Senior Vice President, Chief Financial Officer | 42 | 未披露 | 未持股 | 2025-12-04 |
| Mark Snyder | 男 | Chief Compliance Officer, Corporate Secretary, General Counsel and Senior Vice President | 58 | 未披露 | 未持股 | 2025-12-04 |
| Cortney Caudill | 女 | Senior Vice President and Chief Operating Officer | 49 | 未披露 | 未持股 | 2025-12-04 |
| Helen I. Torley | 女 | Chief Executive Officer, Independent Director and President | 62 | 651.89万美元 | 未持股 | 2025-12-04 |
董事简历
中英对照 | 中文 | 英文- Jean Pierre Bizzari
-
Jean Pierre Bizzari为Halozyme Therapeutics, Inc.董事会提供了30多年的临床肿瘤学和全球药物批准战略专业知识。他从Celgene公司退休，曾于2012年10月至2015年12月担任执行副总裁兼肿瘤学全球主管，并于2008年至2012年10月担任临床开发肿瘤学高级副总裁，负责监督一系列领先的肿瘤产品的开发和批准，包括RVLIMID来那度胺、Vidaza（阿扎胞苷）、Istodax（罗米地辛）和Abraxane（nab-紫杉醇）。在2008年之前，Bizzari博士担任赛诺菲-安万特临床肿瘤学开发副总裁，负责监督Eloxatin（奥沙利铂）、Taxotere（多西他赛）和Elitek（rasburicase）的批准。之前Bizzari博士是Rhne-Poulenc Rorer临床开发肿瘤学副总裁。Bizzari博士是法国国家癌症研究所科学顾问委员会的成员。Bizzari博士自2005年以来一直是法国国家癌症研究所国际科学委员会的成员，自2010年以来一直是法国国家癌症研究所（INCa）的成员。Bizzari博士还担任生物制药公司Transgene SA以及生物技术公司Compugen Ltd.和Nordic Nanovector ASA的董事会成员。在过去五年中，他还曾在生物制药公司Celator Pharmaceuticals, Inc.、生物技术公司iTeos Therapeutics S.A和Pieris制药公司的董事会任职。他还担任Onxeo S.A.的董事会观察员。Bizzari博士是一名医学博士，毕业于尼斯医学院和肿瘤学专家（在多伦多和蒙特利尔接受培训）。Bizzari博士还是巴黎La Piti é-Salp ê tri è re医院肿瘤科的一名助理。
Jean Pierre Bizzari provides Halozyme Therapeutics, Inc. Board of Directors with over 30 years of clinical oncology and global drug approval strategy expertise. He retired from Celgene Corporation having served as Executive Vice President and Global Head of Oncology from October 2012 to December 2015 and as Senior Vice President for Clinical Development Oncology from 2008 to October 2012 and oversaw the development and approval of a number of leading oncology products including REVLIMID lenalidomide, VIDAZA (azacitidine), ISTODAX (romidepsin) and ABRAXANE (nab-paclitaxel). Prior to 2008 Dr. Bizzari served as Vice President, Clinical Oncology Development for Sanofi-Aventis where he oversaw the approval of Eloxatin (oxaliplatin), Taxotere (docetaxel) and Elitek (rasburicase). Previously Dr. Bizzari was Vice President, Clinical Development Oncology for Rhne-Poulenc Rorer. Dr. Bizzari is a member of the Scientific Advisory Board of France's National Cancer Institute. Dr. Bizzari has also been a member of the international scientific committee of the French National Cancer Research Institute since 2005 and the French National Cancer Institute (INCa) since 2010. Dr. Bizzari also serves on the board of directors of Transgene SA, a biopharmaceutical company, and biotechnology companies Compugen Ltd. and Nordic Nanovector ASA. Within the past five years he also served on the board of directors of Celator Pharmaceuticals, Inc., a biopharmaceutical company, and biotechnology companies iTeos Therapeutics S.A, and Pieris Pharmaceuticals, Inc.. He also serves as a board observer at Onxeo S.A. Dr. Bizzari is a Doctor of Medicine and a graduate of the Nice Medical School and a specialist in oncology (training in Toronto and Montreal). Dr. Bizzari was also an assistant in the medical oncology department at La Pitié-Salpêtrière hospital in Paris. - Jean Pierre Bizzari为Halozyme Therapeutics, Inc.董事会提供了30多年的临床肿瘤学和全球药物批准战略专业知识。他从Celgene公司退休，曾于2012年10月至2015年12月担任执行副总裁兼肿瘤学全球主管，并于2008年至2012年10月担任临床开发肿瘤学高级副总裁，负责监督一系列领先的肿瘤产品的开发和批准，包括RVLIMID来那度胺、Vidaza（阿扎胞苷）、Istodax（罗米地辛）和Abraxane（nab-紫杉醇）。在2008年之前，Bizzari博士担任赛诺菲-安万特临床肿瘤学开发副总裁，负责监督Eloxatin（奥沙利铂）、Taxotere（多西他赛）和Elitek（rasburicase）的批准。之前Bizzari博士是Rhne-Poulenc Rorer临床开发肿瘤学副总裁。Bizzari博士是法国国家癌症研究所科学顾问委员会的成员。Bizzari博士自2005年以来一直是法国国家癌症研究所国际科学委员会的成员，自2010年以来一直是法国国家癌症研究所（INCa）的成员。Bizzari博士还担任生物制药公司Transgene SA以及生物技术公司Compugen Ltd.和Nordic Nanovector ASA的董事会成员。在过去五年中，他还曾在生物制药公司Celator Pharmaceuticals, Inc.、生物技术公司iTeos Therapeutics S.A和Pieris制药公司的董事会任职。他还担任Onxeo S.A.的董事会观察员。Bizzari博士是一名医学博士，毕业于尼斯医学院和肿瘤学专家（在多伦多和蒙特利尔接受培训）。Bizzari博士还是巴黎La Piti é-Salp ê tri è re医院肿瘤科的一名助理。
- Jean Pierre Bizzari provides Halozyme Therapeutics, Inc. Board of Directors with over 30 years of clinical oncology and global drug approval strategy expertise. He retired from Celgene Corporation having served as Executive Vice President and Global Head of Oncology from October 2012 to December 2015 and as Senior Vice President for Clinical Development Oncology from 2008 to October 2012 and oversaw the development and approval of a number of leading oncology products including REVLIMID lenalidomide, VIDAZA (azacitidine), ISTODAX (romidepsin) and ABRAXANE (nab-paclitaxel). Prior to 2008 Dr. Bizzari served as Vice President, Clinical Oncology Development for Sanofi-Aventis where he oversaw the approval of Eloxatin (oxaliplatin), Taxotere (docetaxel) and Elitek (rasburicase). Previously Dr. Bizzari was Vice President, Clinical Development Oncology for Rhne-Poulenc Rorer. Dr. Bizzari is a member of the Scientific Advisory Board of France's National Cancer Institute. Dr. Bizzari has also been a member of the international scientific committee of the French National Cancer Research Institute since 2005 and the French National Cancer Institute (INCa) since 2010. Dr. Bizzari also serves on the board of directors of Transgene SA, a biopharmaceutical company, and biotechnology companies Compugen Ltd. and Nordic Nanovector ASA. Within the past five years he also served on the board of directors of Celator Pharmaceuticals, Inc., a biopharmaceutical company, and biotechnology companies iTeos Therapeutics S.A, and Pieris Pharmaceuticals, Inc.. He also serves as a board observer at Onxeo S.A. Dr. Bizzari is a Doctor of Medicine and a graduate of the Nice Medical School and a specialist in oncology (training in Toronto and Montreal). Dr. Bizzari was also an assistant in the medical oncology department at La Pitié-Salpêtrière hospital in Paris.
- Bernadette Connaughton
-
Bernadette Connaughton，从2015年12月起在本公司担任董事之一。她从2014年起，在全球医药公司Bristol-Myers Squibb开始她的职业生涯，目前担任欧洲市场、加拿大和澳大利亚主管。她曾在 Bristol-Myers Squibb担任其它高级领导职位，包括：2013-2014在President-Intercontinental担任总裁；2010-2012在President-Japan, Pacific Rim -Canada 担任总裁；2006-2009在U.S. Cardiovascular/Metabolic Business Unit担任高级副总裁；2004-2005担任Primary Care Marketing高级副总裁。2014年起，在European Markets and Patient Access Committees of the European Federation of Pharmaceutical Industry Associations任职。她持有Johns Hopkins 大学的学士学位以及Pennsylvania大学的工商管理硕士学位。
Bernadette Connaughton,served in senior management position at Bristol-Myers Squibb Pharmaceutical Company, most recently served as president, China, Latin America, Central and Eastern Europe and Middle East. In this position, she developed the multi-year strategy for the successful commercialization of a number of oncology, virology and immunology products, including Opdivo, Yervoy, Sprycel, Daklinza and Orencia. Prior to serving in that role, Ms. Connaughton served as Bristol-Myers Squibb's president, European Markets, Canada and Australia; president, Intercontinental; and president, Japan, Pacific Rim, Australia and Canada; senior vice president, Cardiovascular and Metabolic Business Unit, U.S.; and senior vice president, Primary Care Marketing, U.S. Ms. Connaughton also served on the European Federation of Pharmaceutical Industry Association, Patient Access and European Markets Committees from 2014 to 2016. She received her Bachelor of Arts from Johns Hopkins University and her Master of Business Administration from The Wharton School, University of Pennsylvania. - Bernadette Connaughton，从2015年12月起在本公司担任董事之一。她从2014年起，在全球医药公司Bristol-Myers Squibb开始她的职业生涯，目前担任欧洲市场、加拿大和澳大利亚主管。她曾在 Bristol-Myers Squibb担任其它高级领导职位，包括：2013-2014在President-Intercontinental担任总裁；2010-2012在President-Japan, Pacific Rim -Canada 担任总裁；2006-2009在U.S. Cardiovascular/Metabolic Business Unit担任高级副总裁；2004-2005担任Primary Care Marketing高级副总裁。2014年起，在European Markets and Patient Access Committees of the European Federation of Pharmaceutical Industry Associations任职。她持有Johns Hopkins 大学的学士学位以及Pennsylvania大学的工商管理硕士学位。
- Bernadette Connaughton,served in senior management position at Bristol-Myers Squibb Pharmaceutical Company, most recently served as president, China, Latin America, Central and Eastern Europe and Middle East. In this position, she developed the multi-year strategy for the successful commercialization of a number of oncology, virology and immunology products, including Opdivo, Yervoy, Sprycel, Daklinza and Orencia. Prior to serving in that role, Ms. Connaughton served as Bristol-Myers Squibb's president, European Markets, Canada and Australia; president, Intercontinental; and president, Japan, Pacific Rim, Australia and Canada; senior vice president, Cardiovascular and Metabolic Business Unit, U.S.; and senior vice president, Primary Care Marketing, U.S. Ms. Connaughton also served on the European Federation of Pharmaceutical Industry Association, Patient Access and European Markets Committees from 2014 to 2016. She received her Bachelor of Arts from Johns Hopkins University and her Master of Business Administration from The Wharton School, University of Pennsylvania.
- Moni Miyashita
-
Moni Miyashita，从生物制药公司Intercept Pharmaceuticals, Inc.退休，于2009年5月至2016年6月担任首席财务官和财务主管。从2001年到2009年，Duncan女士在生物技术公司DOV制药公司担任过各种越来越重要的高级领导职务，包括首席财务官，并最终在DOV于2010年出售给Euthymics Bioscience，Inc.之前担任首席执行官。在加入DOV之前，Duncan女士于1998年至2001年在雷曼兄弟公司担任企业财务-全球医疗保健副总裁，并于1994年至1998年在SBC Warburg Dillon Read Inc.担任企业财务总监。她还曾于1989年至1992年在百事可乐公司国际审计部门任职，并于1986年至1989年在德勤会计师事务所审计部门担任注册会计师。邓肯女士获得了路易斯安那州立大学的工商管理硕士学位和宾夕法尼亚大学沃顿商学院的工商管理硕士学位。
Moni Miyashita,retired from Intercept Pharmaceuticals, Inc., a biopharmaceutical company, where she served as Chief Financial Officer and Treasurer from May 2009 to June 2016. From 2001 to 2009, Ms. Duncan held various senior leadership roles of increasing responsibility at DOV Pharmaceutical, Inc., a biotechnology company, including Chief Financial Officer and ultimately serving as Chief Executive Officer prior to DOV's sale in 2010 to Euthymics Bioscience, Inc. Prior to joining DOV, Ms. Duncan served as Vice President of Corporate Finance-Global Healthcare at Lehman Brothers Inc. from 1998 to 2001, and as Director of Corporate Finance at SBC Warburg Dillon Read Inc. from 1994 to 1998. She also worked for PepsiCo, Inc. from 1989 to 1992 in its international audit division, and was a certified public accountant in the audit division of Deloitte & Touche LLP from 1986 to 1989. Ms. Duncan received her BBA from Louisiana State University and her MBA from the Wharton School of the University of Pennsylvania. - Moni Miyashita，从生物制药公司Intercept Pharmaceuticals, Inc.退休，于2009年5月至2016年6月担任首席财务官和财务主管。从2001年到2009年，Duncan女士在生物技术公司DOV制药公司担任过各种越来越重要的高级领导职务，包括首席财务官，并最终在DOV于2010年出售给Euthymics Bioscience，Inc.之前担任首席执行官。在加入DOV之前，Duncan女士于1998年至2001年在雷曼兄弟公司担任企业财务-全球医疗保健副总裁，并于1994年至1998年在SBC Warburg Dillon Read Inc.担任企业财务总监。她还曾于1989年至1992年在百事可乐公司国际审计部门任职，并于1986年至1989年在德勤会计师事务所审计部门担任注册会计师。邓肯女士获得了路易斯安那州立大学的工商管理硕士学位和宾夕法尼亚大学沃顿商学院的工商管理硕士学位。
- Moni Miyashita,retired from Intercept Pharmaceuticals, Inc., a biopharmaceutical company, where she served as Chief Financial Officer and Treasurer from May 2009 to June 2016. From 2001 to 2009, Ms. Duncan held various senior leadership roles of increasing responsibility at DOV Pharmaceutical, Inc., a biotechnology company, including Chief Financial Officer and ultimately serving as Chief Executive Officer prior to DOV's sale in 2010 to Euthymics Bioscience, Inc. Prior to joining DOV, Ms. Duncan served as Vice President of Corporate Finance-Global Healthcare at Lehman Brothers Inc. from 1998 to 2001, and as Director of Corporate Finance at SBC Warburg Dillon Read Inc. from 1994 to 1998. She also worked for PepsiCo, Inc. from 1989 to 1992 in its international audit division, and was a certified public accountant in the audit division of Deloitte & Touche LLP from 1986 to 1989. Ms. Duncan received her BBA from Louisiana State University and her MBA from the Wharton School of the University of Pennsylvania.
- Mahesh Krishnan
-
Mahesh Krishnan，曾在肾透析服务提供商达维塔保健，Inc.担任过各种职务，包括在达维塔保健的技术和研发战略合作伙伴关系以及华盛顿特区的医疗政策等领域担任TERM0 Venture Group的联席主管，该公司是达维塔保健，Inc.的外部创新部门。自2019年5月以来，Krishnan博士还担任达维塔保健的集团研发副总裁，在担任该职务之前，Krishnan博士于2015年至2019年5月担任达维塔保健的首位国际首席医疗官。从2004年到2009年，Krishnan博士曾在跨国生物制药公司安进公司担任过各种职务，包括担任Epogen的全球开发领导并作为执行董事，负责安进所有国内产品的医疗政策。从2000年到2004年，Krishnan博士是弗吉尼亚肾脏病学集团的执业肾病学家。他在托马斯杰斐逊大学杰斐逊医学院获得医学博士学位，在宾夕法尼亚州立大学获得医学预科学士学位。他还拥有约翰霍普金斯大学的硕士学位和约翰霍普金斯大学凯里商学院的医疗保健管理硕士学位。
Mahesh Krishnan,has served in various roles at DaVita, Inc., a provider of kidney dialysis services, including service as the co-lead of DaVita Venture Group, the external innovation arm of DaVita, Inc., where he is responsible for strategic partnerships in technology and research and development at DaVita, as well as medical policy in Washington, D.C. Since May 2019, Dr. Krishnan has also served as DaVita's Group Vice President of Research and Development and prior to that role, Dr. Krishnan served as DaVita's first international Chief Medical Officer from 2015 to May 2019. From 2004 to 2009, Dr. Krishnan served in various roles at Amgen Inc., a multinational biopharmaceutical company, including serving as the Global Development Leader for Epogen and as Executive Director, Medical Policy for all of Amgen's domestic products. From 2000 to 2004, Dr. Krishnan was a practicing nephrologist at Virginia Nephrology Group. He earned his M.D. from Jefferson Medical College at Thomas Jefferson University and his B.S. in pre-medicine from The Pennsylvania State University. He also holds an M.P.H. from Johns Hopkins University and an M.B.A. in health care management from the Johns Hopkins Carey School of Business. - Mahesh Krishnan，曾在肾透析服务提供商达维塔保健，Inc.担任过各种职务，包括在达维塔保健的技术和研发战略合作伙伴关系以及华盛顿特区的医疗政策等领域担任TERM0 Venture Group的联席主管，该公司是达维塔保健，Inc.的外部创新部门。自2019年5月以来，Krishnan博士还担任达维塔保健的集团研发副总裁，在担任该职务之前，Krishnan博士于2015年至2019年5月担任达维塔保健的首位国际首席医疗官。从2004年到2009年，Krishnan博士曾在跨国生物制药公司安进公司担任过各种职务，包括担任Epogen的全球开发领导并作为执行董事，负责安进所有国内产品的医疗政策。从2000年到2004年，Krishnan博士是弗吉尼亚肾脏病学集团的执业肾病学家。他在托马斯杰斐逊大学杰斐逊医学院获得医学博士学位，在宾夕法尼亚州立大学获得医学预科学士学位。他还拥有约翰霍普金斯大学的硕士学位和约翰霍普金斯大学凯里商学院的医疗保健管理硕士学位。
- Mahesh Krishnan,has served in various roles at DaVita, Inc., a provider of kidney dialysis services, including service as the co-lead of DaVita Venture Group, the external innovation arm of DaVita, Inc., where he is responsible for strategic partnerships in technology and research and development at DaVita, as well as medical policy in Washington, D.C. Since May 2019, Dr. Krishnan has also served as DaVita's Group Vice President of Research and Development and prior to that role, Dr. Krishnan served as DaVita's first international Chief Medical Officer from 2015 to May 2019. From 2004 to 2009, Dr. Krishnan served in various roles at Amgen Inc., a multinational biopharmaceutical company, including serving as the Global Development Leader for Epogen and as Executive Director, Medical Policy for all of Amgen's domestic products. From 2000 to 2004, Dr. Krishnan was a practicing nephrologist at Virginia Nephrology Group. He earned his M.D. from Jefferson Medical College at Thomas Jefferson University and his B.S. in pre-medicine from The Pennsylvania State University. He also holds an M.P.H. from Johns Hopkins University and an M.B.A. in health care management from the Johns Hopkins Carey School of Business.
- James Lang
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Connie L. Matsui
-
Connie L. Matsui，2009年1月，她从Biogen Idec 退休，时任知识和创新网络部执行副总裁。她曾担任Biogen Idec及其前身IDEC Pharmaceuticals的执行委员会成员。1992年11月加入IDEC Pharmaceuticals之后她所担任的重要职务有：高级副总裁，负责投资者关系、企业传播、人力资源、项目管理及战略规划；利妥昔单抗Rituxan和MabThera后期开发和商业化的协同主席；负责与Roche 和 Genentech的合作关系；Zevalin的项目负责人，这是第一个美国FDA认证的放射免疫治疗药品。进入生物科技行业之前，她在Wells Fargo Bank从事综合管理、营销及人力资源方面的工作。她活跃于一些非营利机构的董事会，1999-2002年间，她曾是Girl Scouts of the USA 的全国会长/主席。她获得了Stanford University的学士学位和工商管理硕士学位。
Connie L. Matsui retired from Biogen Idec Inc. in January 2009 as the Executive Vice President, Knowledge and Innovation Networks. She served as an Executive Committee member at both Biogen Idec and IDEC Pharmaceuticals, a predecessor of Biogen Idec. Among the major roles she played after joining IDEC Pharmaceuticals in November 1992 were: Senior Vice President, overseeing investor relations, corporate communications, human resources, project management and strategic planning; Collaboration Chair for the late stage development and commercialization of rituximab tradenames: Rituxan and MabThera in partnership with Roche and Genentech; and Project Leader for Zevalin, the first radioimmunotherapy approved by the U.S. FDA. Prior to entering the biotechnology industry, Ms. Matsui worked for Wells Fargo Bank in general management, marketing and human resources. Ms. Matsui has been active on a number of not-for-profit boards at the local, national and global levels. Ms. Matsui serves on the board of directors of biopharmaceutical companies Artelo Biosciences, Inc. and Sutro Biopharma, Inc. Ms. Matsui earned B.A. and M.B.A. degrees from Stanford University. - Connie L. Matsui，2009年1月，她从Biogen Idec 退休，时任知识和创新网络部执行副总裁。她曾担任Biogen Idec及其前身IDEC Pharmaceuticals的执行委员会成员。1992年11月加入IDEC Pharmaceuticals之后她所担任的重要职务有：高级副总裁，负责投资者关系、企业传播、人力资源、项目管理及战略规划；利妥昔单抗Rituxan和MabThera后期开发和商业化的协同主席；负责与Roche 和 Genentech的合作关系；Zevalin的项目负责人，这是第一个美国FDA认证的放射免疫治疗药品。进入生物科技行业之前，她在Wells Fargo Bank从事综合管理、营销及人力资源方面的工作。她活跃于一些非营利机构的董事会，1999-2002年间，她曾是Girl Scouts of the USA 的全国会长/主席。她获得了Stanford University的学士学位和工商管理硕士学位。
- Connie L. Matsui retired from Biogen Idec Inc. in January 2009 as the Executive Vice President, Knowledge and Innovation Networks. She served as an Executive Committee member at both Biogen Idec and IDEC Pharmaceuticals, a predecessor of Biogen Idec. Among the major roles she played after joining IDEC Pharmaceuticals in November 1992 were: Senior Vice President, overseeing investor relations, corporate communications, human resources, project management and strategic planning; Collaboration Chair for the late stage development and commercialization of rituximab tradenames: Rituxan and MabThera in partnership with Roche and Genentech; and Project Leader for Zevalin, the first radioimmunotherapy approved by the U.S. FDA. Prior to entering the biotechnology industry, Ms. Matsui worked for Wells Fargo Bank in general management, marketing and human resources. Ms. Matsui has been active on a number of not-for-profit boards at the local, national and global levels. Ms. Matsui serves on the board of directors of biopharmaceutical companies Artelo Biosciences, Inc. and Sutro Biopharma, Inc. Ms. Matsui earned B.A. and M.B.A. degrees from Stanford University.
- Jeffrey W. Henderson
-
Jeffrey W. Henderson自2015年9月起一直是Berkshire Partners LLC（一家私人股权投资公司）的咨询主任。2005年5月至2014年11月，他曾担任Cardinal Health Inc.（一家保健服务公司）的首席财务官。加盟Cardinal Health之前，Henderson先生在Eli Lilly公司和General Motors担任多个职位，包括担任Eli Lilly Canada的总裁兼总经理，Eli Lilly公司的主管和财务，并且在英国、新加坡、加拿大和美国的General Motors担任管理职位。自2015年8月起，Henderson先生一直担任Halozyme Therapeutics Inc.的董事；自2015年8月起，担任FibroGen, Inc.的董事。Henderson学生持有Kettering University电气工程的学士学位；Harvard Business School的工商管理硕士学位。
Jeffrey W. Henderson,has served as President of JWH Consulting LLC, an investment and business advisory firm, since January 2018. From 2015 to 2019, he served as a Healthcare Advisory Director to Berkshire Partners LLC. Mr. Henderson previously served as the Chief Financial Officer of Cardinal Health, Inc., a multinational health care services company, from May 2005 to November 2014, and in an executive capacity until his retirement from Cardinal in August 2015. From 1998 to 2005, Mr. Henderson held various senior management positions at Eli Lilly and Company, a multinational pharmaceutical company, including President and General Manager, Eli Lilly Canada, Inc. and Controller and Treasurer of Eli Lilly, Inc. He received his BS in electrical engineering from Kettering University, Flint, Mich., and his MBA from Harvard Graduate School of Business Administration. - Jeffrey W. Henderson自2015年9月起一直是Berkshire Partners LLC（一家私人股权投资公司）的咨询主任。2005年5月至2014年11月，他曾担任Cardinal Health Inc.（一家保健服务公司）的首席财务官。加盟Cardinal Health之前，Henderson先生在Eli Lilly公司和General Motors担任多个职位，包括担任Eli Lilly Canada的总裁兼总经理，Eli Lilly公司的主管和财务，并且在英国、新加坡、加拿大和美国的General Motors担任管理职位。自2015年8月起，Henderson先生一直担任Halozyme Therapeutics Inc.的董事；自2015年8月起，担任FibroGen, Inc.的董事。Henderson学生持有Kettering University电气工程的学士学位；Harvard Business School的工商管理硕士学位。
- Jeffrey W. Henderson,has served as President of JWH Consulting LLC, an investment and business advisory firm, since January 2018. From 2015 to 2019, he served as a Healthcare Advisory Director to Berkshire Partners LLC. Mr. Henderson previously served as the Chief Financial Officer of Cardinal Health, Inc., a multinational health care services company, from May 2005 to November 2014, and in an executive capacity until his retirement from Cardinal in August 2015. From 1998 to 2005, Mr. Henderson held various senior management positions at Eli Lilly and Company, a multinational pharmaceutical company, including President and General Manager, Eli Lilly Canada, Inc. and Controller and Treasurer of Eli Lilly, Inc. He received his BS in electrical engineering from Kettering University, Flint, Mich., and his MBA from Harvard Graduate School of Business Administration.
- Barbara Duncan
-
Barbara Duncan，自2009年5月起担任Atea Pharmaceuticals, Inc.的首席财务官，自2010年起担任Atea Pharmaceuticals, Inc.的财务主管。她有着超过15年的生命科学行业经验。Duncan女士于2009年5月至2016年6月在Intercept Pharmaceuticals，Inc.担任首席财务官兼财务主管。Duncan女士自2016年6月起担任Jounce Therapeutics，Inc.董事会成员，自2016年6月起担任Adaptimmune Therapeutics PLC.董事会成员，自2016年11月起担任Obseva S.A.董事会成员，自2017年6月起担任Ovid Therapeutics，Inc.董事会成员。自2001年至2009年4月，Duncan女士担任了DOV Pharmaceutical, Inc.， 或 DOV的首席财务官后来是首席执行官，该公司是一家生物制药公司，关注中枢神经系统异常，并于2010年被Euthymics Bioscience, Inc.收购。在加入DOV之前，从1998年8月至2001年8月，Duncan女士担任了Lehman Brothers Inc.的公司财务部担任副总裁，主要为生命科学和一般工业行业提供金融咨询服务。从1994年9月至1998年8月，Duncan女士担任了SBC Warburg Dillon Read, Inc.公司财务部的助理和董事，主要关注生命科学和一般工业行业的构建兼并、资产剥离和融资。1989年至1992年间，她也在PepsiCo, Inc.的国际审计部门工作；1986年至1989年间，也是Deloitte & Touche LLP审计部门的注册会计师。Duncan女士于1985年获得了Louisiana State University的学士学位，1994年获得了 Wharton School, University of Pennsylvania的工商管理硕士学位。她早前曾担任DOV的董事，目前是Edgemont Pharmaceuticals, LLC的董事，该公司是一家私人专业制药公司，主要关注神经科学领域。Duncan女士获得了路易斯安那州立大学的文学学士学位，宾夕法尼亚大学沃顿商学院的文学硕士学位。
Barbara Duncan,served as the Chief Financial Officer and Treasurer at Intercept Pharmaceuticals, Inc., a publicly held biopharmaceutical company from May 2009 to July 2016. Prior to Intercept, Ms. Duncan held various senior leadership roles of increasing responsibility at DOV Pharmaceutical, Inc., a biotechnology company, including Chief Financial Officer and ultimately serving as Chief Executive Officer prior to DOV's sale to Euthymics Bioscience, Inc., a biopharmaceutical company, in 2010. Ms. Duncan has also held roles in the corporate finance groups at SBC Warburg Dillon Read, Inc. and Lehman Brothers Inc. She currently serves on the boards of directors of Halozyme Therapeutics, Inc., Atea Pharmaceuticals, Inc. and Fusion Pharmaceuticals Inc., and previously served on the board of directors of Adaptimmune Therapeutics plc, Immunomedics, Inc., Jounce Therapeutics, Inc., ObsEva SA, Innoviva, Inc. and Aevi Genomic Medicine, Inc. Ms. Duncan received her BS from Louisiana State University and her MBA from the Wharton School of the University of Pennsylvania. - Barbara Duncan，自2009年5月起担任Atea Pharmaceuticals, Inc.的首席财务官，自2010年起担任Atea Pharmaceuticals, Inc.的财务主管。她有着超过15年的生命科学行业经验。Duncan女士于2009年5月至2016年6月在Intercept Pharmaceuticals，Inc.担任首席财务官兼财务主管。Duncan女士自2016年6月起担任Jounce Therapeutics，Inc.董事会成员，自2016年6月起担任Adaptimmune Therapeutics PLC.董事会成员，自2016年11月起担任Obseva S.A.董事会成员，自2017年6月起担任Ovid Therapeutics，Inc.董事会成员。自2001年至2009年4月，Duncan女士担任了DOV Pharmaceutical, Inc.， 或 DOV的首席财务官后来是首席执行官，该公司是一家生物制药公司，关注中枢神经系统异常，并于2010年被Euthymics Bioscience, Inc.收购。在加入DOV之前，从1998年8月至2001年8月，Duncan女士担任了Lehman Brothers Inc.的公司财务部担任副总裁，主要为生命科学和一般工业行业提供金融咨询服务。从1994年9月至1998年8月，Duncan女士担任了SBC Warburg Dillon Read, Inc.公司财务部的助理和董事，主要关注生命科学和一般工业行业的构建兼并、资产剥离和融资。1989年至1992年间，她也在PepsiCo, Inc.的国际审计部门工作；1986年至1989年间，也是Deloitte & Touche LLP审计部门的注册会计师。Duncan女士于1985年获得了Louisiana State University的学士学位，1994年获得了 Wharton School, University of Pennsylvania的工商管理硕士学位。她早前曾担任DOV的董事，目前是Edgemont Pharmaceuticals, LLC的董事，该公司是一家私人专业制药公司，主要关注神经科学领域。Duncan女士获得了路易斯安那州立大学的文学学士学位，宾夕法尼亚大学沃顿商学院的文学硕士学位。
- Barbara Duncan,served as the Chief Financial Officer and Treasurer at Intercept Pharmaceuticals, Inc., a publicly held biopharmaceutical company from May 2009 to July 2016. Prior to Intercept, Ms. Duncan held various senior leadership roles of increasing responsibility at DOV Pharmaceutical, Inc., a biotechnology company, including Chief Financial Officer and ultimately serving as Chief Executive Officer prior to DOV's sale to Euthymics Bioscience, Inc., a biopharmaceutical company, in 2010. Ms. Duncan has also held roles in the corporate finance groups at SBC Warburg Dillon Read, Inc. and Lehman Brothers Inc. She currently serves on the boards of directors of Halozyme Therapeutics, Inc., Atea Pharmaceuticals, Inc. and Fusion Pharmaceuticals Inc., and previously served on the board of directors of Adaptimmune Therapeutics plc, Immunomedics, Inc., Jounce Therapeutics, Inc., ObsEva SA, Innoviva, Inc. and Aevi Genomic Medicine, Inc. Ms. Duncan received her BS from Louisiana State University and her MBA from the Wharton School of the University of Pennsylvania.
- Matthew L. Posard
-
Matthew L. Posard，为本公司的董事会带来丰富的生命科学行业销售和营销方面的经验。他现为Illumina 新兴机会业务部的高级副总裁、总经理，负责公司技术的开发，并使之应用于新市场。2006年，他加入Illumina，担任全球营销副总裁；2007-2011，他担任全球销售副总裁，成功的领导该公司进入生命科学商业市场。加入Illumina之前，他在Gen-Probe担任过各种战略和产品营销方面的职务，帮助该公司在DNA探针为基础的传染病诊断和血库市场获得领先的地位。之前，他曾负责Biosite的全球营销，帮助成功引进该公司的BNP充血性心脏衰竭的生物标志物，以及与Beckman Coulter的联合营销协作。他获得了University of California, San Diego的数量经济与决策学学士学位。
Matthew L. Posard,is Founding Principal of Explore DNA, a life sciences executive consulting firm, a position he has held since March 2016. Since 2017, he has provided advisory services to CEOs for several emerging life sciences companies. From February 2017 to April 2018, Mr. Posard served as President and Chief Commercial Officer of GenePeeks, Inc., a genetic research company. From March 2015 to April 2016, he served as Chief Commercial Officer of Trovagene, Inc., a molecular diagnostic biotechnology company. From February 2006 to February 2015, he held various commercial and general management positions at Illumina, Inc., a genomics company focusing on DNA sequencing, including senior executive positions overseeing Global Sales, Marketing, and General Manager of Clinical and Consumer Genomics as well as New and Emerging Markets. Mr. Posard holds a BA degree in Management Science from the University of San Diego. - Matthew L. Posard，为本公司的董事会带来丰富的生命科学行业销售和营销方面的经验。他现为Illumina 新兴机会业务部的高级副总裁、总经理，负责公司技术的开发，并使之应用于新市场。2006年，他加入Illumina，担任全球营销副总裁；2007-2011，他担任全球销售副总裁，成功的领导该公司进入生命科学商业市场。加入Illumina之前，他在Gen-Probe担任过各种战略和产品营销方面的职务，帮助该公司在DNA探针为基础的传染病诊断和血库市场获得领先的地位。之前，他曾负责Biosite的全球营销，帮助成功引进该公司的BNP充血性心脏衰竭的生物标志物，以及与Beckman Coulter的联合营销协作。他获得了University of California, San Diego的数量经济与决策学学士学位。
- Matthew L. Posard,is Founding Principal of Explore DNA, a life sciences executive consulting firm, a position he has held since March 2016. Since 2017, he has provided advisory services to CEOs for several emerging life sciences companies. From February 2017 to April 2018, Mr. Posard served as President and Chief Commercial Officer of GenePeeks, Inc., a genetic research company. From March 2015 to April 2016, he served as Chief Commercial Officer of Trovagene, Inc., a molecular diagnostic biotechnology company. From February 2006 to February 2015, he held various commercial and general management positions at Illumina, Inc., a genomics company focusing on DNA sequencing, including senior executive positions overseeing Global Sales, Marketing, and General Manager of Clinical and Consumer Genomics as well as New and Emerging Markets. Mr. Posard holds a BA degree in Management Science from the University of San Diego.
- Helen I. Torley
-
Helen I. Torley，总裁、首席执行官、董事。她在2014年1月加入Halozyme，担任总裁、首席执行官、董事。职业生涯期间，她领导过一些产品的成功上市，包括Kyprolis、Prolia、Sensipar、Miacalcin。之前，她曾是Onyx Pharmaceuticals Onyx的执行副总裁、首席商业官，负责Nexavar和Stivarga产品与Bayer的合作，以及Kyprolis的美国上市。她曾在 Onyx工作，负责美国以外的市场，尤其是欧洲的商业发展。加入 Onyx之前，她在Amgen担任了14年的管理职务，曾担任美国肾脏病业务部和美国骨骼健康业务部的总经理。 1997-2002，她在Bristol-Myers Squibb担任过各种高级管理职位，包括心血管疾病和代谢销售区域副总裁、心血管全球市场营销部总监。她在Sandoz/Novartis开始职业生涯，最终的职务是医疗事务副总裁，制定并实行包括肿瘤的所有治疗领域的上市后临床研究。进入这个行业之前，她在苏格兰格拉斯哥的Royal Infirmary从事医疗工作，担任风湿病科的高级常务官。她获得了University of Glasgow的医学学士学位、外科学士学位，是Royal College of Physicians （M.R.C.P）的成员。
Helen I. Torley,joined Halozyme in January 2014 as President and Chief Executive Officer and as a member of Halozyme's Board of Directors. Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis, Prolia, Sensipar, and Miacalcin. Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals ("Onyx") from August 2011 to December 2013 overseeing the collaboration with Bayer on Nexavar and Stivarga and the U.S. launch of Kyprolis. She was responsible for the development of Onyx's commercial capabilities in ex-U.S. markets and in particular, in Europe. Prior to Onyx, Dr. Torley spent 10 years in management positions at Amgen Inc., most recently serving as Vice President and General Manager of the U.S. Nephrology Business Unit from 2003 to 2009 and the U.S. Bone Health Business Unit from 2009 to 2011. From 1997 to 2002, she held various senior management positions at Bristol-Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. She began her career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, developing and conducting post-marketing clinical studies across all therapeutic areas, including oncology. Within the past five years, Dr. Torley served on the Board of Directors of Quest Diagnostics Incorporated, a diagnostic information services company. Before joining the industry, Dr. Torley was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland. Dr. Torley received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B.) from the University of Glasgow and is a Member of the Royal College of Physicians (M.R.C.P). - Helen I. Torley，总裁、首席执行官、董事。她在2014年1月加入Halozyme，担任总裁、首席执行官、董事。职业生涯期间，她领导过一些产品的成功上市，包括Kyprolis、Prolia、Sensipar、Miacalcin。之前，她曾是Onyx Pharmaceuticals Onyx的执行副总裁、首席商业官，负责Nexavar和Stivarga产品与Bayer的合作，以及Kyprolis的美国上市。她曾在 Onyx工作，负责美国以外的市场，尤其是欧洲的商业发展。加入 Onyx之前，她在Amgen担任了14年的管理职务，曾担任美国肾脏病业务部和美国骨骼健康业务部的总经理。 1997-2002，她在Bristol-Myers Squibb担任过各种高级管理职位，包括心血管疾病和代谢销售区域副总裁、心血管全球市场营销部总监。她在Sandoz/Novartis开始职业生涯，最终的职务是医疗事务副总裁，制定并实行包括肿瘤的所有治疗领域的上市后临床研究。进入这个行业之前，她在苏格兰格拉斯哥的Royal Infirmary从事医疗工作，担任风湿病科的高级常务官。她获得了University of Glasgow的医学学士学位、外科学士学位，是Royal College of Physicians （M.R.C.P）的成员。
- Helen I. Torley,joined Halozyme in January 2014 as President and Chief Executive Officer and as a member of Halozyme's Board of Directors. Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis, Prolia, Sensipar, and Miacalcin. Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals ("Onyx") from August 2011 to December 2013 overseeing the collaboration with Bayer on Nexavar and Stivarga and the U.S. launch of Kyprolis. She was responsible for the development of Onyx's commercial capabilities in ex-U.S. markets and in particular, in Europe. Prior to Onyx, Dr. Torley spent 10 years in management positions at Amgen Inc., most recently serving as Vice President and General Manager of the U.S. Nephrology Business Unit from 2003 to 2009 and the U.S. Bone Health Business Unit from 2009 to 2011. From 1997 to 2002, she held various senior management positions at Bristol-Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. She began her career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, developing and conducting post-marketing clinical studies across all therapeutic areas, including oncology. Within the past five years, Dr. Torley served on the Board of Directors of Quest Diagnostics Incorporated, a diagnostic information services company. Before joining the industry, Dr. Torley was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland. Dr. Torley received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B.) from the University of Glasgow and is a Member of the Royal College of Physicians (M.R.C.P).
高管简历
中英对照 | 中文 | 英文- Nicole LaBrosse
Nicole LaBrosse，高级副总裁兼首席财务官。LaBrosse女士自2022年2月起担任高级副总裁兼首席财务官，拥有超过19年的公共会计和公司融资经验。她曾于2020年1月至2022年2月担任公司财务和会计副总裁，并于2017年7月至2019年12月担任公司执行董事兼财务总监。2015年6月至2017年6月，她担任公司财务报告高级总监。在加入公司之前，LaBrosse女士曾于2004年至2015年在普华永道会计师事务所担任审计员。她在本特利学院获得公司财务和会计学士学位和会计学硕士学位后，获得了注册公共会计执照。
Nicole LaBrosse,has served as the Senior Vice President, Chief Financial Officer since February 2022 and has over 20 years of public accounting and corporate finance experience. She previously served as the Company's Vice President, Finance and Accounting from January 2020 to February 2022 and as the Company's Executive Director, Controller from July 2017 to December 2019. From June 2015 to June 2017, she was the Company's Senior Director, Financial Reporting. Prior to joining the Company, Ms. LaBrosse was an auditor with PricewaterhouseCoopers, LLP from 2004 to 2015. She received a certified public accounting license after receiving a B.S. degree in corporate finance and accounting and her M.S. degree in accounting from Bentley College.- Nicole LaBrosse，高级副总裁兼首席财务官。LaBrosse女士自2022年2月起担任高级副总裁兼首席财务官，拥有超过19年的公共会计和公司融资经验。她曾于2020年1月至2022年2月担任公司财务和会计副总裁，并于2017年7月至2019年12月担任公司执行董事兼财务总监。2015年6月至2017年6月，她担任公司财务报告高级总监。在加入公司之前，LaBrosse女士曾于2004年至2015年在普华永道会计师事务所担任审计员。她在本特利学院获得公司财务和会计学士学位和会计学硕士学位后，获得了注册公共会计执照。
- Nicole LaBrosse,has served as the Senior Vice President, Chief Financial Officer since February 2022 and has over 20 years of public accounting and corporate finance experience. She previously served as the Company's Vice President, Finance and Accounting from January 2020 to February 2022 and as the Company's Executive Director, Controller from July 2017 to December 2019. From June 2015 to June 2017, she was the Company's Senior Director, Financial Reporting. Prior to joining the Company, Ms. LaBrosse was an auditor with PricewaterhouseCoopers, LLP from 2004 to 2015. She received a certified public accounting license after receiving a B.S. degree in corporate finance and accounting and her M.S. degree in accounting from Bentley College.
- Mark Snyder
Mark Snyder，高级副总裁、总法律顾问、首席合规官兼秘书。Snyder先生于2022年1月加入Halozyme，担任高级副总裁、总法律顾问、首席合规官和秘书。Snyder先生在法律和商业管理方面拥有30多年的经验。在2008年1月至2021年12月加入Halozyme之前，Snyder先生曾在无线通信公司Qualcomm Incorporated的法律部门担任过多个高级职位，包括2016年4月至2021年12月担任高级副总裁兼诉讼副总法律顾问，2010年10月至2016年4月担任专利顾问副总裁。在加入高通之前，斯奈德曾在无线通信公司京瓷无线公司担任首席知识产权顾问，并在两家较小的公司担任法律和商业管理职务。斯奈德先生的法律生涯始于Sheridan Ross & McIntosh律师事务所的专利律师。Snyder先生在罗切斯特大学获得化学工程学士学位，在波士顿学院卡罗尔商学院获得工商管理硕士学位。他在波士顿学院法学院获得法学博士学位。
Mark Snyder,joined Halozyme in January 2022 as Senior Vice President, General Counsel, Chief Compliance Officer and Secretary. Mr. Snyder has over 30 years of experience in legal and business management roles. Prior to joining Halozyme, from January 2008 to December 2021, Mr. Snyder served in various senior positions in the legal department at Qualcomm Incorporated, a wireless communications company, including his most recent positions as Senior Vice President & Deputy General Counsel, Litigation, from April 2016 to December 2021 and Vice President, Patent Counsel, from October 2010 to April 2016. Before Qualcomm, Mr. Snyder served as Lead Intellectual Property Counsel at Kyocera Wireless Corp., a wireless communications company, and has held legal and business management roles in two smaller companies. Mr. Snyder began his legal career as a patent attorney at the law firm of Sheridan Ross & McIntosh. Mr. Snyder received his B.S. degree in chemical engineering at the University of Rochester and his M.B.A. degree from Boston College Carroll School of Business. He received his J.D. from Boston College Law School.- Mark Snyder，高级副总裁、总法律顾问、首席合规官兼秘书。Snyder先生于2022年1月加入Halozyme，担任高级副总裁、总法律顾问、首席合规官和秘书。Snyder先生在法律和商业管理方面拥有30多年的经验。在2008年1月至2021年12月加入Halozyme之前，Snyder先生曾在无线通信公司Qualcomm Incorporated的法律部门担任过多个高级职位，包括2016年4月至2021年12月担任高级副总裁兼诉讼副总法律顾问，2010年10月至2016年4月担任专利顾问副总裁。在加入高通之前，斯奈德曾在无线通信公司京瓷无线公司担任首席知识产权顾问，并在两家较小的公司担任法律和商业管理职务。斯奈德先生的法律生涯始于Sheridan Ross & McIntosh律师事务所的专利律师。Snyder先生在罗切斯特大学获得化学工程学士学位，在波士顿学院卡罗尔商学院获得工商管理硕士学位。他在波士顿学院法学院获得法学博士学位。
- Mark Snyder,joined Halozyme in January 2022 as Senior Vice President, General Counsel, Chief Compliance Officer and Secretary. Mr. Snyder has over 30 years of experience in legal and business management roles. Prior to joining Halozyme, from January 2008 to December 2021, Mr. Snyder served in various senior positions in the legal department at Qualcomm Incorporated, a wireless communications company, including his most recent positions as Senior Vice President & Deputy General Counsel, Litigation, from April 2016 to December 2021 and Vice President, Patent Counsel, from October 2010 to April 2016. Before Qualcomm, Mr. Snyder served as Lead Intellectual Property Counsel at Kyocera Wireless Corp., a wireless communications company, and has held legal and business management roles in two smaller companies. Mr. Snyder began his legal career as a patent attorney at the law firm of Sheridan Ross & McIntosh. Mr. Snyder received his B.S. degree in chemical engineering at the University of Rochester and his M.B.A. degree from Boston College Carroll School of Business. He received his J.D. from Boston College Law School.
- Cortney Caudill
Cortney Caudill，自2023年10月起担任公司高级副总裁、首席运营官。在加入公司之前，从2019年到2023年10月，Caudill女士在生物技术公司Aeglea生物制药公司担任的职务责任越来越大，包括制造副总裁、技术运营高级副总裁，最近担任首席产品官。从2002年到2018年，她在凯姆布雷克斯生物科学、Vaxagen，Inc.、Genentech、Vetter Pharma International、Samsung Biologics、Baxalta和Eaulife NA等多家生命科学公司担任越来越多的运营职务。她在得克萨斯大学获得生物学学士学位和心理学学士学位。
Cortney Caudill,has served as the Company's Senior Vice President, Chief Operations Officer since October 2023. Prior to joining the Company, from 2019 to October 2023, Ms. Caudill served in roles with increasing responsibility at Aeglea Biotherapeutics, Inc., a biotechnology company, including Vice President of Manufacturing, Senior Vice President, Technical Operations and most recently as Chief Product Officer. From 2002 to 2018, she held operational roles of increasing responsibility at various life sciences companies such as Cambrex Bioscience, Vaxagen, Inc., Genentech, Vetter Pharma International, Samsung Biologics, Baxalta and Eaulife NA. She received her B.S. degree in biology and her B.A degree in psychology from the University of Texas.- Cortney Caudill，自2023年10月起担任公司高级副总裁、首席运营官。在加入公司之前，从2019年到2023年10月，Caudill女士在生物技术公司Aeglea生物制药公司担任的职务责任越来越大，包括制造副总裁、技术运营高级副总裁，最近担任首席产品官。从2002年到2018年，她在凯姆布雷克斯生物科学、Vaxagen，Inc.、Genentech、Vetter Pharma International、Samsung Biologics、Baxalta和Eaulife NA等多家生命科学公司担任越来越多的运营职务。她在得克萨斯大学获得生物学学士学位和心理学学士学位。
- Cortney Caudill,has served as the Company's Senior Vice President, Chief Operations Officer since October 2023. Prior to joining the Company, from 2019 to October 2023, Ms. Caudill served in roles with increasing responsibility at Aeglea Biotherapeutics, Inc., a biotechnology company, including Vice President of Manufacturing, Senior Vice President, Technical Operations and most recently as Chief Product Officer. From 2002 to 2018, she held operational roles of increasing responsibility at various life sciences companies such as Cambrex Bioscience, Vaxagen, Inc., Genentech, Vetter Pharma International, Samsung Biologics, Baxalta and Eaulife NA. She received her B.S. degree in biology and her B.A degree in psychology from the University of Texas.
- Helen I. Torley
Helen I. Torley，总裁、首席执行官、董事。她在2014年1月加入Halozyme，担任总裁、首席执行官、董事。职业生涯期间，她领导过一些产品的成功上市，包括Kyprolis、Prolia、Sensipar、Miacalcin。之前，她曾是Onyx Pharmaceuticals Onyx的执行副总裁、首席商业官，负责Nexavar和Stivarga产品与Bayer的合作，以及Kyprolis的美国上市。她曾在 Onyx工作，负责美国以外的市场，尤其是欧洲的商业发展。加入 Onyx之前，她在Amgen担任了14年的管理职务，曾担任美国肾脏病业务部和美国骨骼健康业务部的总经理。 1997-2002，她在Bristol-Myers Squibb担任过各种高级管理职位，包括心血管疾病和代谢销售区域副总裁、心血管全球市场营销部总监。她在Sandoz/Novartis开始职业生涯，最终的职务是医疗事务副总裁，制定并实行包括肿瘤的所有治疗领域的上市后临床研究。进入这个行业之前，她在苏格兰格拉斯哥的Royal Infirmary从事医疗工作，担任风湿病科的高级常务官。她获得了University of Glasgow的医学学士学位、外科学士学位，是Royal College of Physicians （M.R.C.P）的成员。
Helen I. Torley,joined Halozyme in January 2014 as President and Chief Executive Officer and as a member of Halozyme's Board of Directors. Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis, Prolia, Sensipar, and Miacalcin. Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals ("Onyx") from August 2011 to December 2013 overseeing the collaboration with Bayer on Nexavar and Stivarga and the U.S. launch of Kyprolis. She was responsible for the development of Onyx's commercial capabilities in ex-U.S. markets and in particular, in Europe. Prior to Onyx, Dr. Torley spent 10 years in management positions at Amgen Inc., most recently serving as Vice President and General Manager of the U.S. Nephrology Business Unit from 2003 to 2009 and the U.S. Bone Health Business Unit from 2009 to 2011. From 1997 to 2002, she held various senior management positions at Bristol-Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. She began her career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, developing and conducting post-marketing clinical studies across all therapeutic areas, including oncology. Within the past five years, Dr. Torley served on the Board of Directors of Quest Diagnostics Incorporated, a diagnostic information services company. Before joining the industry, Dr. Torley was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland. Dr. Torley received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B.) from the University of Glasgow and is a Member of the Royal College of Physicians (M.R.C.P).- Helen I. Torley，总裁、首席执行官、董事。她在2014年1月加入Halozyme，担任总裁、首席执行官、董事。职业生涯期间，她领导过一些产品的成功上市，包括Kyprolis、Prolia、Sensipar、Miacalcin。之前，她曾是Onyx Pharmaceuticals Onyx的执行副总裁、首席商业官，负责Nexavar和Stivarga产品与Bayer的合作，以及Kyprolis的美国上市。她曾在 Onyx工作，负责美国以外的市场，尤其是欧洲的商业发展。加入 Onyx之前，她在Amgen担任了14年的管理职务，曾担任美国肾脏病业务部和美国骨骼健康业务部的总经理。 1997-2002，她在Bristol-Myers Squibb担任过各种高级管理职位，包括心血管疾病和代谢销售区域副总裁、心血管全球市场营销部总监。她在Sandoz/Novartis开始职业生涯，最终的职务是医疗事务副总裁，制定并实行包括肿瘤的所有治疗领域的上市后临床研究。进入这个行业之前，她在苏格兰格拉斯哥的Royal Infirmary从事医疗工作，担任风湿病科的高级常务官。她获得了University of Glasgow的医学学士学位、外科学士学位，是Royal College of Physicians （M.R.C.P）的成员。
- Helen I. Torley,joined Halozyme in January 2014 as President and Chief Executive Officer and as a member of Halozyme's Board of Directors. Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis, Prolia, Sensipar, and Miacalcin. Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals ("Onyx") from August 2011 to December 2013 overseeing the collaboration with Bayer on Nexavar and Stivarga and the U.S. launch of Kyprolis. She was responsible for the development of Onyx's commercial capabilities in ex-U.S. markets and in particular, in Europe. Prior to Onyx, Dr. Torley spent 10 years in management positions at Amgen Inc., most recently serving as Vice President and General Manager of the U.S. Nephrology Business Unit from 2003 to 2009 and the U.S. Bone Health Business Unit from 2009 to 2011. From 1997 to 2002, she held various senior management positions at Bristol-Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. She began her career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, developing and conducting post-marketing clinical studies across all therapeutic areas, including oncology. Within the past five years, Dr. Torley served on the Board of Directors of Quest Diagnostics Incorporated, a diagnostic information services company. Before joining the industry, Dr. Torley was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland. Dr. Torley received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B.) from the University of Glasgow and is a Member of the Royal College of Physicians (M.R.C.P).